Shots:

• The P-III OPTIMUM study results involve assessing of Ponesimod (20 mg) vs Aubagio (teriflunomide- 14mg) in 1-133 patients with relapsing MS for 108wks. at 162 sites across the globe
• The P-III OPTIMUM study results: 30.5% reduction in ARR (0.202 vs 0.290); 56% reduction in the number of CUALs; @12wks. CDA (10.1% vs 12.4%); safety profile is consistent with the previous studies
• Ponesimod is an investigational S1P1 modulator- act by inhibiting S1P activity leading to a reduction in the number of circulating lymphocytes with its expected regulatory submission to the US FDA and EMA as a treatment for RMS based on the OPTIMUM study results

Click here to­ read full press release/ article

Ref: Johnson & Johnson | Image: Janssen